CD8A and neoplasm: In addition, Kyn and Kyn derivatives can bind the aryl hydrocarbon receptor (AhR) [18], which has been shown to impair the proliferation and function of various immune effectors, including CD8+ T lymphocytes, and provide tumor cells with a means to evade anticancer immunosurveillance [19].